课题基金 / 基金详情

ACTIVITY OF SOFT GELATIN CAPSULE OF SAQUINAVIR IN COMBINATION

ACTIVITY OF SOFT GELATIN CAPSULE OF SAQUINAVIR IN COMBINATION
沙奎那韦组合软明胶胶囊的活性
批准号：
6291143
负责人：
JOSEPH WHEAT
金额：
$0.04万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6291143
关键词：
AIDS therapy HIV infections antiAIDS agent combination chemotherapy delavirdine drug screening /evaluation human immunodeficiency virus human therapy evaluation indinavir protease inhibitor ritonavir saquinavir virus RNA

项目摘要

项目成果

JOSEPH WHEAT的其他基金

相似基金

相关文献

中文摘要
翻译
这是一项随机、多中心、部分盲法试验，涉及六种方案的沙奎那韦软胶囊(SQVSGC)与利托那韦或奈非那韦以及地拉韦丁和/或阿德福韦酯的组合。治疗时间约为24周。研究对象是以前使用过依地那韦和感染了HIV-1RNA的艾滋病毒，OR=2,000和=200,000拷贝/毫升。随机化将包括通过筛选HIV-RNA拷贝数(=2,000-20,000拷贝/毫升与20,000-200,000拷贝/毫升)进行分层。
英文摘要
This is a randomized multi-center and partially blinded trial of six regimens of the soft gelatin capsule of saquinavir (SQVSGC) in combination with ritonavir or nelfinavir and combinations of delavirdine, and/or adefovir dipivoxil. The treatments will be for 24 weeks approximately. Study subjects are HIV infected with prior indinavir use and with HIV-1 RNA >or = 2,000 and <,= 200,000 copies/mL. The randomization will include stratification by screening HIV-RNA copy number (>,= 2,000 - 20,000 copies/mL versus > 20,000- 200,000 copies/mL).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DAPSONE AND ATOVAQUONE FOR PROPHYLAXIS AGAINST PCP
THALIDOMIDE FOR TREATMENT OF ORAL/ESOPHAGEAL APHTHYOUS ULCERS AND HIV VIREMIA
AMBISOME VS AMPHOTERICIN B FOLLOWED BY FLUCONAZOLE IN TREATMENT OF MENINGITIS
CS96 209 SCH56592 VERSUS FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDA
海外基金